155 related articles for article (PubMed ID: 2696193)
1. Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer.
Yagoda A; Bander NH
Urol Int; 1989; 44(6):338-45. PubMed ID: 2696193
[TBL] [Abstract][Full Text] [Related]
2. Interferon treatment of renal cell carcinoma. Current status and future prospects.
Krown SE
Cancer; 1987 Feb; 59(3 Suppl):647-51. PubMed ID: 10822464
[TBL] [Abstract][Full Text] [Related]
3. New treatment approaches for metastatic renal cell carcinoma.
Nanus DM
Curr Oncol Rep; 2000 Sep; 2(5):417-22. PubMed ID: 11122873
[TBL] [Abstract][Full Text] [Related]
4. Phase II cytotoxic chemotherapy trials in renal cell carcinoma: 1983-1988.
Yagoda A
Prog Clin Biol Res; 1990; 350():227-41. PubMed ID: 2201045
[No Abstract] [Full Text] [Related]
5. In focus: bevacizumab for renal cell carcinoma.
Clin Adv Hematol Oncol; 2005 Jan; 3(1):68-9. PubMed ID: 16166971
[No Abstract] [Full Text] [Related]
6. Cytotoxic chemotherapy for advanced renal cell carcinoma.
Yagoda A; Petrylak D; Thompson S
Urol Clin North Am; 1993 May; 20(2):303-21. PubMed ID: 8493752
[TBL] [Abstract][Full Text] [Related]
7. Renal cell carcinoma and interferon at the millennium.
Pastore RD; Pfeffer LM; Nanus DM
Cancer Invest; 2001; 19(3):281-91. PubMed ID: 11338886
[No Abstract] [Full Text] [Related]
8. [Drug treatment of metastatic renal cell carcinoma].
Rafiyan MR; Jäger E
Dtsch Med Wochenschr; 2013 Aug; 138(31-32):1567-70. PubMed ID: 23836159
[No Abstract] [Full Text] [Related]
9. [Outlook: Future therapy of renal cell carcinoma].
Bergmann L; Miller K
Onkologie; 2010; 33 Suppl 1():18-20. PubMed ID: 20164673
[TBL] [Abstract][Full Text] [Related]
10. New therapeutic approaches in the management of metastatic renal cell carcinoma.
Gkialas IK; Papadopoulos G
J BUON; 2009; 14(3):399-404. PubMed ID: 19810129
[TBL] [Abstract][Full Text] [Related]
11. The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma.
Frey K; Schliemann C; Schwager K; Giavazzi R; Johannsen M; Neri D
J Urol; 2010 Dec; 184(6):2540-8. PubMed ID: 21030045
[TBL] [Abstract][Full Text] [Related]
12. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.
Buti S; Bersanelli M
Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416
[No Abstract] [Full Text] [Related]
13. Can outpatient interleukin-2 and interferon replace high-dose interleukin-2 for metastatic renal cell carcinoma?
Vieweg J
Nat Clin Pract Oncol; 2005 Apr; 2(4):192-3. PubMed ID: 16264932
[No Abstract] [Full Text] [Related]
14. Cabozantinib and nivolumab for renal cell carcinoma.
Worley L
Lancet Oncol; 2015 Nov; 16(15):e531. PubMed ID: 26481805
[No Abstract] [Full Text] [Related]
15. Novel investigative approaches for advanced renal cell carcinoma.
Berg WJ; Divgi CR; Nanus DM; Motzer RJ
Semin Oncol; 2000 Apr; 27(2):234-9. PubMed ID: 10768602
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Advanced Renal-Cell Carcinoma.
Santini D; Tonini G
N Engl J Med; 2016 Mar; 374(9):888-9. PubMed ID: 26962913
[No Abstract] [Full Text] [Related]
17. Treatment of Advanced Renal-Cell Carcinoma.
Huillard O; Alexandre J; Goldwasser F
N Engl J Med; 2016 Mar; 374(9):888. PubMed ID: 26962912
[No Abstract] [Full Text] [Related]
18. Treatment of Advanced Renal-Cell Carcinoma.
Motzer RJ; Escudier B; Choueiri TK
N Engl J Med; 2016 Mar; 374(9):889-90. PubMed ID: 26962911
[No Abstract] [Full Text] [Related]
19. Regression of metastatic clear cell kidney cancer with interleukin-2 treatment following nivolumab (anti-PD-1) treatment.
Brayer J; Fishman M
J Immunother; 2014 Apr; 37(3):187-91. PubMed ID: 24598453
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implications of polymorphisms and interleukin-2 therapy for renal cell carcinoma.
Gardner TA; Logan T
J Urol; 2009 Aug; 182(2):425-6. PubMed ID: 19524946
[No Abstract] [Full Text] [Related]
[Next] [New Search]
